产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
首页 制药产品大全 生物制品 生物技术服务 Fast, Efficient...

Fast, Efficient, High-Yield Fueling Biologics R&D

2026-02-27

产品详情

Fast, Efficient, High-Yield Fueling Biologics R&D
药物开发技术
中国药典
药用级
CHO瞬时蛋白表达系统
1
中国,北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,非洲

产品描述

JSBio's Trans CHO Kit Pro includes an upgraded Trans CHO (Basal Medium), and ALLY Feed 100 (Feed Medium). These are completely chemically defined media, free of serum, hydrolysates, and any animal-derived components. The components are synergistically optimized to maximize protein expression yield.

Product Information

Key Features

  • Upgraded basal medium Trans CHO: Chemically defined, suitable for various CHO cell subtypes, free of animal-derived components and hydrolysates, ensuring high-quality and high-density suspension culture.
  • Feed medium ALLY Feed 100: Used in combination with the basal medium, significantly enhances antibody expression yield and quality.
  • Expression enhancer CHO Enhancer: Promotes rapid protein production within a short timeframe.
  • High-efficiency transfection reagent Trans 1: Optimized transfection protocol ensures fast and efficient gene integration.

Key Benefits

Case Studies

Trans CHO Kit Pro supports high-efficiency expression of antigens and antibodies. Transfection of CHO-K1 cells was performed at a density of 6 × 10⁶ cells/mL. Experimental results demonstrating the performance of Trans CHO Kit Pro are shown below.

CHO-K1 Cell Transfection Efficiency/Cell Viability Test

Figure 1. Comparison of transient transfection efficiency/cell viability between Trans CHO Kit Pro and PEI transfection in CHO-K1 cells.

Figure 2. Comparison between Trans CHO Kit Pro and the control group (PEI).

Trans CHO Kit Pro demonstrated significantly higher transfection efficiency than the PEI transfection reagent (40 kDa).

Protein Yield

Figure 3. Protein yields comparison for different molecule types between Trans CHO Kit Pro and competitor’s media (control).

When applied to CHO-K1 cells, Trans CHO Kit Pro showed significantly higher yields than that of competitor's media. The yield of Molecule 1 reached 1.4 g/L on day 6.

Comparison of Different Transfection Protocols: Case 1

Figure 4. Comparison of protein yield on day 7, electroporation vs. Trans CHO Kit Pro.

For the same protein molecule and expression time, Trans CHO Kit Pro achieved twice the protein yield comparing to electroporation method.

Comparison of Different Transfection Protocols: Case 2

Figure 5. Comparison of protein yield on day 5 among Competitor's media (control) , Electroporation and Trans CHO Kit Pro.

Transient transfection with Trans CHO Kit Pro consistently showed significantly higher protein yield than both competitor's media (control) and electroporation protocols across different projects. Notably, in Project D, the protein yield reached 2 g/L on day 5.

Contact Us:

Tel: 4000046572

E-mail: marketing@jianshunbio.com

Web: www.jianshunbio.com

澳斯康生物(南通)股份有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

澳斯康生物(南通)股份有限公司是生物药规模化合规生产整体解决方案提供者,业务涵盖生物制药 CDMO 业务板块、细胞培养基业务板块与早研服务。公司由知名生物医药专家罗顺博士创立,拥有一支技术能力全面、经验丰富且高度国际化的管理及技术团队,其中多位来自 Amgen、Genentech、BI、Pfizer、BMS、BI 及 Merck 等行业知名企业。公司现有员工近600人,技术人员占比超过70%(含研发、生产、质量),在长期发展中,培养出一大批掌握核心技术的本土生物技术人才。在生物制药 CDMO 板块,澳斯康生物能够提供从候选分子到临床及商业化生产的一站式 CMC 解决方案。目前,该板块在江苏南通、上海临港设有 GMP 生产基地,提供包括单抗、双抗、融合蛋白、ADC 等药物的一站式研发生产服务。细胞培养基业务板块,为国内领先的无血清培养基品牌-健顺生物。健顺生物专注于无血清、个性化、化学成分界定细胞培养基的研发、生产和销售,同时为客户提供细胞培养工艺开发与放大、培养基配方委托生产等完整的上游解决方案。其在江苏南通、甘肃兰州及韩国拥有培养基生产基地,年产能达到千吨级,产品和技术服务主要应用于重组蛋白、抗体类药物,人 / 兽用疫苗以及细胞治疗领域。早研服务板块,借助落地于上海张江的 Ginspire 健士拜生物推进。健士拜生物专注于早研服务,针对不同形式创新分子提供分子设计、分子评估、分子优化、结构功能表征等服务。通过与客户合作开发差异化创新分子,或按需对自主开发分子进行对外授权,可从结构功能、药理药效、成药性等多维度评估优化,提高复杂创新分子开发成功率,更高效地推动优选分子进入下一阶段开发。
业务类型:
成立日期:
年营业额:
主营产品类别: